Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.59 |
| ▸ | HTR2C | P28335 | 15/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23116665 | 0.90 | HTR2A (0.73) | HTR2AHTR2CMAPKAPK2HTR2B | |
| SCHEMBL23138523 | 0.86 | HTR2B (0.47) | HTR2AHTR2CGRIN2BHTR2BKDM4E | |
| SCHEMBL23116663 | 0.85 | HTR2A (0.60) | HTR2AHTR2CMAPKAPK2GRIN2B | |
| Hydrochloric Acid SCHEMBL23116673 | 0.85 | HTR2B (0.49) | HTR2AHTR2CGRIN2BHTR2BKDM4E | |
| SCHEMBL23116677 | 0.83 | MAPT (0.66) | HTR2AHTR2CMAPKAPK2HTR2BKDM4E | |
| SCHEMBL18669422 | 0.82 | GRIN2B (0.65) | HTR2AHTR2CMAPKAPK2GRIN2B | |
| SCHEMBL23116654 | 0.81 | HTR2A (0.58) | HTR2AHTR2CMAPKAPK2HTR2BKDM4E | |
| SCHEMBL23116678 | 0.79 | HTR2B (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL14917262 | 0.78 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL10086583 | 0.78 | HTR2A (0.75) | HTR2AHTR2CMAPKAPK2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORP (US) | 2024-09-19 | — | — | US | disclosed |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3352566-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | Minerva Biotechnologies Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017053886-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017053886-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | HTR2A 4495/4885HTR2C 4518/4885MAPKAPK2 322/4885 |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MCL1, CRABP2, MYADM | HTR2A 4495/4885HTR2C 4518/4885MAPKAPK2 322/4885 |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | HTR2A 4615/4885HTR2C 4566/4885MAPKAPK2 719/4885 |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | HTR2A 4495/4885HTR2C 4518/4885MAPKAPK2 322/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | HTR2A 4440/4885HTR2C 4453/4885MAPKAPK2 565/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR2A 4440/4885HTR2C 4453/4885MAPKAPK2 565/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | HTR2A 3307/4885HTR2C 1923/4885MAPKAPK2 3550/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR2A 4440/4885HTR2C 4453/4885MAPKAPK2 565/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR2A 4440/4885HTR2C 4453/4885MAPKAPK2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.